Eli Lilly and Competitors

Eli Lilly and (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Earnings and Valuation

This table compares Eli Lilly and and Johnson & Johnson's gross revenue, earnings per share and valuation.

Johnson & Johnson has higher revenue and earnings than Eli Lilly and. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Eli Lilly and and Johnson & Johnson, as provided by MarketBeat.com.

Eli Lilly and currently has a consensus target price of $231.2857, indicating a potential downside of 5.02%. Johnson & Johnson has a consensus target price of $190.3750, indicating a potential upside of 10.55%. Given Johnson & Johnson's higher possible upside, analysts plainly believe Johnson & Johnson is more favorable than Eli Lilly and.

Dividends

Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.5%. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and has increased its dividend for 1 consecutive years and Johnson & Johnson has increased its dividend for 59 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

81.6% of Eli Lilly and shares are held by institutional investors. Comparatively, 66.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Eli Lilly and and Johnson & Johnson's net margins, return on equity and return on assets.

Risk & Volatility

Eli Lilly and has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.

Summary

Eli Lilly and beats Johnson & Johnson on 10 of the 18 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Pfizer and Eli Lilly and's revenue, earnings per share and valuation.

Pfizer has higher revenue and earnings than Eli Lilly and. Pfizer is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Pfizer and Eli Lilly and, as reported by MarketBeat.

Pfizer currently has a consensus price target of $43.0833, indicating a potential upside of 0.64%. Eli Lilly and has a consensus price target of $231.2857, indicating a potential downside of 5.02%. Given Pfizer's higher possible upside, equities research analysts plainly believe Pfizer is more favorable than Eli Lilly and.

Dividends

Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 3.6%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. Pfizer pays out 70.3% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 1 consecutive years and Eli Lilly and has increased its dividend for 1 consecutive years.

Institutional & Insider Ownership

64.1% of Pfizer shares are owned by institutional investors. Comparatively, 81.6% of Eli Lilly and shares are owned by institutional investors. 0.1% of Pfizer shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Pfizer and Eli Lilly and's net margins, return on equity and return on assets.

Volatility and Risk

Pfizer has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

Summary

Eli Lilly and beats Pfizer on 12 of the 17 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares AbbVie and Eli Lilly and's revenue, earnings per share and valuation.

Eli Lilly and has lower revenue, but higher earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for AbbVie and Eli Lilly and, as reported by MarketBeat.

AbbVie currently has a consensus price target of $121.6733, indicating a potential upside of 4.62%. Eli Lilly and has a consensus price target of $231.2857, indicating a potential downside of 5.02%. Given AbbVie's higher possible upside, equities research analysts plainly believe AbbVie is more favorable than Eli Lilly and.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. AbbVie pays out 49.2% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 49 consecutive years and Eli Lilly and has increased its dividend for 1 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

66.0% of AbbVie shares are owned by institutional investors. Comparatively, 81.6% of Eli Lilly and shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares AbbVie and Eli Lilly and's net margins, return on equity and return on assets.

Volatility and Risk

AbbVie has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

Summary

Eli Lilly and beats AbbVie on 10 of the 18 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Merck & Co., Inc. and Eli Lilly and's revenue, earnings per share and valuation.

Merck & Co., Inc. has higher revenue and earnings than Eli Lilly and. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Merck & Co., Inc. and Eli Lilly and, as reported by MarketBeat.

Merck & Co., Inc. currently has a consensus price target of $94.7238, indicating a potential upside of 23.23%. Eli Lilly and has a consensus price target of $231.2857, indicating a potential downside of 5.02%. Given Merck & Co., Inc.'s higher possible upside, equities research analysts plainly believe Merck & Co., Inc. is more favorable than Eli Lilly and.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. Merck & Co., Inc. pays out 43.8% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 1 consecutive years and Eli Lilly and has increased its dividend for 1 consecutive years.

Institutional & Insider Ownership

71.7% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 81.6% of Eli Lilly and shares are owned by institutional investors. 0.3% of Merck & Co., Inc. shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Merck & Co., Inc. and Eli Lilly and's net margins, return on equity and return on assets.

Volatility and Risk

Merck & Co., Inc. has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

Summary

Eli Lilly and beats Merck & Co., Inc. on 11 of the 17 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 2.9%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. Bristol-Myers Squibb pays out 30.4% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and Eli Lilly and has increased its dividend for 1 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares Bristol-Myers Squibb and Eli Lilly and's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Bristol-Myers Squibb and Eli Lilly and's revenue, earnings per share and valuation.

Eli Lilly and has lower revenue, but higher earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Bristol-Myers Squibb and Eli Lilly and, as reported by MarketBeat.

Bristol-Myers Squibb currently has a consensus price target of $74.30, indicating a potential upside of 9.47%. Eli Lilly and has a consensus price target of $231.2857, indicating a potential downside of 5.02%. Given Bristol-Myers Squibb's higher possible upside, equities research analysts plainly believe Bristol-Myers Squibb is more favorable than Eli Lilly and.

Institutional & Insider Ownership

71.5% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 81.6% of Eli Lilly and shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Bristol-Myers Squibb has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

Summary

Eli Lilly and beats Bristol-Myers Squibb on 11 of the 16 factors compared between the two stocks.

Zoetis (NYSE:ZTS) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Dividends

Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. Zoetis pays out 26.0% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has increased its dividend for 1 consecutive years and Eli Lilly and has increased its dividend for 1 consecutive years.

Profitability

This table compares Zoetis and Eli Lilly and's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Zoetis and Eli Lilly and's revenue, earnings per share and valuation.

Eli Lilly and has higher revenue and earnings than Zoetis. Eli Lilly and is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Zoetis and Eli Lilly and, as reported by MarketBeat.com.

Zoetis presently has a consensus price target of $188.75, suggesting a potential downside of 6.88%. Eli Lilly and has a consensus price target of $231.2857, suggesting a potential downside of 5.02%. Given Eli Lilly and's stronger consensus rating and higher possible upside, analysts clearly believe Eli Lilly and is more favorable than Zoetis.

Institutional & Insider Ownership

90.0% of Zoetis shares are held by institutional investors. Comparatively, 81.6% of Eli Lilly and shares are held by institutional investors. 0.2% of Zoetis shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Zoetis has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500.

Summary

Eli Lilly and beats Zoetis on 10 of the 17 factors compared between the two stocks.